Glioblastoma Multiforme
Conditions
Interventions
Case series:Metformin Plus Temozolomide
Sponsors
Sun Yat-sen University Cancer Center
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: (1) Histologically confirmed GBM at first; (2) The patient has received STUPP standard treatment; (3) Recurrent glioblastoma conformed by histopathological or radiological diagnosis; (4) Aged 18 to 70 years; (5) Karnofsky score >=60; (6) Expected survival period is more than 3 months; (7) Normal in hematological finding, heart, liver, lung and kidney function; blood: white blood cell >3.0x10^9/L, platelet count >80x10^9/L, hemoglobin >11g/dl, liver function: serum bilirubin 1.5 ULN, alt and AST <2.5 ULN, blood creatinine <=1.5mg/dl; PT/PTT 1.5 ULN; (8) Signature of informed consent.
Exclusion criteria
Exclusion criteria: (1) History of type I or type II Diabetes; (2) Has contraindications for the use of metformin; (3) History of one of the following metabolic diseases: primary carnitine deficiency, type I or II carnitine transferase deficiency, beta oxidation deficiency, short chain acyl dehydrogenase deficiency, medium chain acyl dehydrogenase deficiency, long chain 3-hydroxyacyl Kievase A deficiency, medium chain acyl Kievase A deficiency, Pyruvateboxa deficiency, porphyrin deficiency; (4) With severe Dyslipidemia: total cholesterol >6.47 mmol/L, triglyceride >5.65 mmol/L; (5) Chemotherapy Intolerance; (6) Pregnant of breast feeding; (7) History of other malignancies; (8) History of Schizophrenia; (9) Can not perform MRI examination; (10) Past cancer-related toxicity did not return to baseline levels.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Progression Free Survival; | — |
Secondary
| Measure | Time frame |
|---|---|
| Overall Survival;Quality Of Life; | — |
Countries
China
Contacts
Public ContactZhenghe Chen
Sun Yat-sen University Cancer Center
Outcome results
None listed